PANEL: How minimizing participant burden leads to on-time enrollment and completion

  • Patient reimbursement: how to relieve financial pressures on patients participating in trials
  • Where are the main hurdles patients face and how can these be removed?
  • Addressing low levels of health literacy in the patient population: how to improve communication
  • Engaging patients and advocacy groups early on in the clinical trial design process

 

Clinical trials surged in H1 2025! Where was the growth, will it continue and how to stay ahead

GlobalData’s clinical trials data indicates that trials initiations in H1 2025 increased significantly over previous years. Public reporting of clinical trials make it easy to miss when and where the real growth is happening. In addition to surprising Wall Street, this has shaken up the competitive landscape and created major opportunities for CROs, CDMOs and Pharma Tech.

  • What drove the surge
  • Where the next wave is coming from
  • How can early signals give you the edge
  • Whether you run trials, manufacture at scale, or partner with life sciences companies, this is about being prepared.

PANEL: How do we work together to deliver GenAI for clinical trials?

  • How AI and digitalization can support streamlining of clinical operations and improve efficiency
  • Simple ways to implement tools such as GPT and GenAI
  • Where can AI be utilized to minimize workloads and increase overall output?
  • The regulatory landscape in the US for the use of AI in clinical trials: what do you need to know?
  • Key limitations of GenAI and how these impact its potential uses for clinical trials in the US

PANEL: AI and machine learning in clinical trials: where are we in 2025?

  • Opportunities for incorporating AI into clinical research: where should the industry be focusing?
  • Why has pharma been relatively slow to utilize AI in clinical research?
  • Understanding limitations of GenAI: what do you need to be wary of?
  • Real case studies on AI in the clinical trial industry: where has there been progress and success?
  • What does the future hold for AI in clinical trials?

MODERATOR Revati Tatake, Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData Healthcare

Strength meets agility: Co-developing a framework for seamless FSO to FSP transition

  • Big pharma is a battleship in a speedboat world. FSP outsourcing offers the agility to cut through traditional development timelines and chart a faster course to patients.
  • In this presentation, Parexel will share how they partnered with Bristol Myers Squibb (BMS) to make a strategic shift, transitioning from a predominantly full-service outsourcing model to a functional service provider model. This involved redefining traditional roles, innovating tasks and responsibilities, and talent redeployment in support of pipeline priorities.
  • The presenters will discuss the strategic considerations and benefits of this transition, demonstrating how through a collaborative partnership, they worked to enhance BMS’ clinical trial operations, creating resource efficiencies, increasing agility, and optimizing clinical operations across their global portfolio. This presentation will offer valuable insights for companies seeking to adapt their outsourcing strategies to meet the demands of today’s complex and rapidly changing drug development environment.

Oversight for all: achieve data transparency with elluminate

Learn how the elluminate Clinical Data Cloud provides seamless access to comprehensive trial data across systems and sources:

  • How a centralized data workbench eradicates data silos and provides near real-time access to data for optimized oversight and more efficient, data-driven decision making
  • AI/ML capabilities to ensure data quality, automated data review processes, and increased productivity across the clinical development lifecycle with eIQ Review
  • Proactive trial oversight and management with increased automation, comprehensive analytics, and custom visualizations in elluminate Operational Insights
  • Mitigating risk with efficiency, accuracy, and ease with holistic Risk-Based Quality Management